'An eye for an eye' therapeutic strategy for cavernous sinus dural arteriovenous fistula: a single-center experience

医学 栓塞 动静脉瘘 单中心 外科 瘘管 海绵窦 眼上静脉 放射科
作者
Liang Xu,Jingwei Zheng,Chenhan Ling,Xianyi Chen,Bing Fang,Cong Qian,Jing Xu,Jun Yu
出处
期刊:Journal of NeuroInterventional Surgery [BMJ]
卷期号:: jnis-021343
标识
DOI:10.1136/jnis-2023-021343
摘要

Background In cavernous sinus dural arteriovenous fistulas (CS-DAVF), ophthalmological symptoms are usually the main clinical presentation, caused by abnormal drainage of the superior ophthalmic vein (SOV). Early opacification of the SOV during cerebral angiography inevitably signifies the fistula’s shunt point at the confluence of the SOV and CS. We aimed to leverage this anatomical feature to achieve precise embolization, thereby enhancing the embolization success rate and preventing CS-related symptoms and complications resulting from overpacking. Methods This single-center, case series study was conducted between May 2017 and September 2023, and included the largest sample of CS-DAVF patients treated via the transfemoral vein-SOV approach. We retrospectively reviewed the data of 32 CS-DAVF patients with inferior petrosal sinus (IPS) occlusion. Results The study demonstrated an excellent immediate postoperative complete embolization rate (31/32, 97%). Only three patients (3/32, 9%) developed temporary endovascular treatment-related complications. The average operation time was 131.6±61.6 min, with an average of 1.2±1.1 coils and 1.8±1.2 mL Onyx glue used per patient. CS-DAVF-associated ophthalmological symptoms resolved in all patients. We also identified a rare anatomical variation, where 77% of the patients had a facial vein draining into the external jugular vein. Conclusions Transfemoral vein-SOV embolization should be considered a crucial alternative approach in CS-DAVF patients with occluded IPS and predominantly SOV drainage. This approach showed an excellent immediate postoperative complete embolization rate and satisfactory long-term outcomes along with clinical safety. We therefore strongly advocate for this ‘an eye for an eye’ treatment strategy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
orixero应助xiaoma采纳,获得10
2秒前
无花果应助科研通管家采纳,获得10
2秒前
上官若男应助科研通管家采纳,获得10
3秒前
Jasper应助陶醉的蜜蜂采纳,获得10
3秒前
小二郎应助科研通管家采纳,获得10
3秒前
3秒前
科研通AI2S应助科研通管家采纳,获得10
3秒前
JamesPei应助科研通管家采纳,获得10
3秒前
NexusExplorer应助科研通管家采纳,获得10
3秒前
Hello应助科研通管家采纳,获得10
3秒前
3秒前
HEIKU应助科研通管家采纳,获得10
3秒前
HEIKU应助科研通管家采纳,获得10
3秒前
完美世界应助科研通管家采纳,获得10
3秒前
思源应助科研通管家采纳,获得10
3秒前
毛豆爸爸应助科研通管家采纳,获得20
3秒前
3秒前
小蘑菇应助科研通管家采纳,获得10
3秒前
科研通AI2S应助科研通管家采纳,获得10
3秒前
毛豆爸爸应助科研通管家采纳,获得20
3秒前
3秒前
3秒前
3秒前
立夏发布了新的文献求助10
3秒前
4秒前
鲤鱼冬灵完成签到,获得积分10
5秒前
cookieMichael给cookieMichael的求助进行了留言
6秒前
星辰大海应助安然采纳,获得10
6秒前
明理青丝发布了新的文献求助10
7秒前
7秒前
晓风完成签到,获得积分10
7秒前
CJ完成签到,获得积分10
7秒前
迅速友容完成签到,获得积分10
8秒前
8秒前
ChouNen完成签到,获得积分10
8秒前
林红豆关注了科研通微信公众号
9秒前
奕初阳发布了新的文献求助10
9秒前
昱珂完成签到,获得积分10
10秒前
周琦关注了科研通微信公众号
11秒前
安晓麒完成签到,获得积分20
12秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi 400
Classics in Total Synthesis IV 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3150244
求助须知:如何正确求助?哪些是违规求助? 2801374
关于积分的说明 7844178
捐赠科研通 2458888
什么是DOI,文献DOI怎么找? 1308710
科研通“疑难数据库(出版商)”最低求助积分说明 628562
版权声明 601721